Denali Therapeutics Inc. (DNLI) Stock Forecast & Analysis

Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Denali Therapeutics Inc. (DNLI:NASDAQ), powered by AI.

Current Price
$23.94
P/E Ratio
-8.0
Market Cap
4.1B
Sector
Healthcare
What is the Denali Therapeutics Inc. stock price forecast?

Denali Therapeutics Inc. is currently trading at $23.94. View real-time AI analysis on Alpha Lenz.

What is Denali Therapeutics Inc. insider trading activity?

View the latest insider trading data for Denali Therapeutics Inc. on Alpha Lenz.

What is Denali Therapeutics Inc.'s P/E ratio?

Denali Therapeutics Inc.'s P/E ratio is -8.0.

Denali Therapeutics Inc.

NASDAQ · DNLI
$23.94+0.09(+0.38%)LiveNASDAQ regular session 09:30–16:00 ET
Ask about Denali Therapeutics Inc.'s future dividend policy...
Alpha Chat Insight

Denali Therapeutics Inc. trades at a P/E of -8.0 (undervalued) with modest ROE of -45.7%.

Ask for details

Company Overview

Denali Therapeutics Inc. is a biotechnology company focused on discovering and developing therapeutic interventions for neurodegenerative diseases. The primary aim of the company is to combat disorders linked to degeneration of the nervous system, such as Alzheimer's, Parkinson's, and ALS, by targeting and addressing underlying mechanisms of these diseases. Denali Therapeutics employs a unique engineering-driven approach, leveraging its deep understanding of biological pathways to create therapies that can cross the blood-brain barrier, an essential obstacle in the treatment of central nervous system diseases. Based in South San Francisco, California, Denali Therapeutics is at the forefront of the biotech industry, collaborating with research institutions and other pharmaceutical companies to advance its pipeline of potential treatments. Its work is pivotal in addressing unmet medical needs related to neurodegeneration, positioning the company as an important player in the pursuit of innovative healthcare solutions aimed at improving the quality of life for affected patients.

CEODr. Ryan J. Watts Ph.D.
SectorHealthcare
IndustryBiotechnology
Employees486

Company Statistics

FY 2025

Profile

$4.12BMarket Cap
$0.00Revenue
0.00Shares Out
486Employees

Margins

N/AGross
N/AEBITDA
N/AOperating
N/APre-Tax
N/ANet

Valuation

-8.03P/E
4.06P/B
N/AEV/Sales
-7.31EV/EBITDA
-9.76P/FCF

Growth (CAGR)

N/ARev 3Yr
N/ARev 5Yr
N/AOp Inc 3Yr
N/AOp Inc 5Yr
N/ANet Inc 3Yr
N/ANet Inc 5Yr

Returns

-40.69%ROA
-45.69%ROE
-44.09%ROIC

Financial Health

$205.33MCash & Cash Equivalents
$-74.23MNet Debt
12.93%Debt/Equity
N/AInterest Cov

Frequently Asked Questions

Denali Therapeutics Inc. (ticker: DNLI) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 486 employees. Market cap is $4.1B.

The current price is $23.94 with a P/E ratio of -8.03x and P/B of 4.06x.

ROE is -45.69%.

Alpha Lenz
Singapore
Treasurer Pte Ltd | License: 202346277E
9 Straits View Marina One West Tower #05-07 Singapore 018937
contact@treasurer.co.kr
©2026 Treasurer Pte Ltd. All rights reserved.
Denali Therapeutics Inc. (DNLI) Stock Forecast 2026 $23.94 — Price, Financials & Analyst Targets | Alpha Lenz